Chinese drug developer JHL Biotech has announced that it randomized its first patient in a phase 3 study of JHL1101, a proposed biosimilar rituximab referencing Rituxan.
Chinese drug developer JHL Biotech has announced that it randomized its first patient in a phase 3 study of JHL1101, a proposed biosimilar rituximab referencing Rituxan.
The phase 3 study in diffuse large B-cell lymphoma (DLBCL) is a multinational, randomized, double-blind, positive-controlled, parallel-group clinical trial comparing the efficacy and safety of the proposed biosimilar with that of the reference, both in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP). JHL indicated that it will seek approval of indications for the treatment of rheumatoid arthritis as well as of lymphomas.
When announcing the trial, Racho Jordanov, chief executive officer of JHL Biotech, said in a statement, "Rituximab is an important biologic for the treatment of lymphoma and rheumatoid arthritis. Unfortunately, it is very expensive for patients and healthcare payers. JHL1101 would provide an affordable treatment for these patients. This is a significant milestone for JHL, and a step forward in our goal to become a global leader in developing, manufacturing, and commercializing biologics."
JHL indicated that the trial would be conducted in Europe, China, and other Asian nations. The announcement of the first randomization follows a July 2018 receipt of positive scientific advice from the European Medicines Agency’s Committee for Medicinal Products for Human Use that allowed the drug maker to move forward with its study in Europe.
Announcement of the phase 3 trial comes as JHL is facing serious scrutiny of its biosimilar programs after it was revealed that several of its employees, all former staffers of the Roche subsidiary Genentech, had been indicted in the United States in connection with the theft of trade secrets related to reference biologics.
According to an October statement issued by the United States Attorney’s Office in San Francisco, California, Xanthe Lam, a principal scientist at the Roche, conspired with her husband and fellow former employee Allen Lam, as well as with John Chan, another former employee, to steal Roche and Genentech’s information related to the reference rituximab, as well as several other biologics.
Genentech has filed a motion in the United States district court for the Northern District of California seeking an injunction to block JHL from making or selling any of the proposed biosimilars for which the indicted parties allegedly stole information, as Genentech alleges that JHL wrongly benefitted from its proprietary data.
If convicted of stealing trade secrets in order to funnel them to JHL for the development of biosimilars, the former Genentech workers each face as many as 10 years in prison.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Study: More Biosimilar Competition Is Not Lowering Patient OOP Costs
March 29th 2024Despite more biosimilars entering the market and generating significant savings for payers and health care systems, these savings are not resulting in lower out-of-pocket (OOP) costs for patients, according to a recent study.
Biosimilar Business Roundup for October 2023—Podcast Edition
November 5th 2023On this episode, we discuss the biggest news to come out of October 2023, including 3 regulatory approvals, 2 complete response letters, and new data and industry insights that have the potential to impact the entire US biosimilar industry.
Coherus Biosciences Cites Biosimilars as Main Drivers of 2023 Revenue Growth
March 14th 2024In its earnings report for the fourth quarter and full year of 2023, Coherus Biosciences detailed its rising revenue growth, which it partly attributed to increased sales for its pegfilgrastim and ranibizumab biosimilars.